Ovid Therapeutics Inc
OVID
Get informed when a big investor buys or sells
+ FollowMarket Cap$332.35M
Close$
$-1.97
180.2% downside
Current Fair Value
180.2% downsideOvervalued by 180.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $332.35 Million |
|---|---|
| Enterprise Value | $239.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.24 |
| Beta | 0.19 |
| Outstanding Shares | 73,735,606 |
Return
| Return on Equity | -12.19% |
|---|---|
| Return on Assets | -10.71% |
| Return on Invested Capital | -22.64% |
Valuation & Multiples
| P/E Ratio | -7.29 |
|---|---|
| PEG | -11.04 |
| Price to Sales | - |
| Price to Book Ratio | 1.23 |
| Enterprise Value to Revenue | 33.66 |
| Enterprise Value to EBIT | -5.05 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$56,667
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$35,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6257▲ 137.34% |
|---|---|
| Total Calls | 110,600▼ 10.01% |
| Total Puts | 179,800▲ 480.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 142.49%▲ 55.48% |
|---|---|
| Total Invested | $233.18M▲ 131.58% |
| Investors Holding | 109▲ 19.00% |
ESG Score
No data
About Ovid Therapeutics Inc
CEO: Jeremy Levin